Literature DB >> 21184830

Patterns of cortical thickness and surface area in early Parkinson's disease.

Thomas Jubault1, Jean-François Gagnon, Sherif Karama, Alain Ptito, Anne-Louise Lafontaine, Alan C Evans, Oury Monchi.   

Abstract

Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder diagnosed on the basis of motor symptoms, but that also includes cognitive and visuo-spatial deficits. Though PD is known to initially affect subcortical regions, the cortex also exhibits neuronal loss in the course of the disease as post mortem studies have shown. So far, PD-related pattern of cortical damage remains unclear, because of disease-caused heterogeneity, and also in part because of methodological issues such as the limitations of Voxel Based Morphometry. Here corticometry was used, a technique that decouples local surface from thickness, to obtain a better picture of PD corticomorphometric patterns. We acquired MRI volumes for 33 healthy controls (HC) and 49 PD patients, extracted local cortical thickness and surface area and modeled both of them as a function of group and age for each participant. Cortical thickness averaged on the whole cortex did not differ between the two groups while mean surface area was significantly larger in the PD group. The bilateral parietal lobule, the right superior frontal gyrus, the left cingulate cortex and the left insular cortex exhibited larger local surface area in the PD group. The right precuneus exhibited cortical thinning associated with age in the PD group and not in the HC group. Furthermore, cortical thinning was observed in the PD group compared with the control group in the left medial supplementary motor area (SMA) and in the right dorsal pre-SMA. Finally, we found the left temporal pole thickness to correlate with disease duration, as well as the bilateral occipital cortex and Broca's area. These results suggest that PD etiology is associated with specific cortical alterations, which could account for cognitive deficits that arise as the disease evolves. Finally, our results observed in the occipital cortex as a function of disease duration may indicate the increase in PD-related visuo-spatial deficits, which can sometimes result in hallucinations later on in the disease. In the future, MRI-generated corticometry, combined with additional behavioral markers, may prove to be a useful diagnosis tool to characterize the evolution of motor and cognitive deficits in PD.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21184830     DOI: 10.1016/j.neuroimage.2010.12.043

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  65 in total

Review 1.  A review of neuroimaging findings in repetitive brain trauma.

Authors:  Inga K Koerte; Alexander P Lin; Anna Willems; Marc Muehlmann; Jakob Hufschmidt; Michael J Coleman; Isobel Green; Huijun Liao; David F Tate; Elisabeth A Wilde; Ofer Pasternak; Sylvain Bouix; Yogesh Rathi; Erin D Bigler; Robert A Stern; Martha E Shenton
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

2.  Improved Automatic Morphology-Based Classification of Parkinson's Disease and Progressive Supranuclear Palsy.

Authors:  Aron S Talai; Zahinoor Ismail; Jan Sedlacik; Kai Boelmans; Nils D Forkert
Journal:  Clin Neuroradiol       Date:  2018-09-14       Impact factor: 3.649

3.  Resting state functional connectivity of the subthalamic nucleus in Parkinson's disease assessed using arterial spin-labeled perfusion fMRI.

Authors:  María A Fernández-Seara; Elisa Mengual; Marta Vidorreta; Gabriel Castellanos; Jaione Irigoyen; Elena Erro; María A Pastor
Journal:  Hum Brain Mapp       Date:  2015-01-30       Impact factor: 5.038

4.  Gray Matter Abnormalities in Idiopathic Parkinson's Disease: Evaluation by Diffusional Kurtosis Imaging and Neurite Orientation Dispersion and Density Imaging.

Authors:  Koji Kamagata; Andrew Zalesky; Taku Hatano; Ryo Ueda; Maria Angelique Di Biase; Ayami Okuzumi; Keigo Shimoji; Masaaki Hori; Karen Caeyenberghs; Christos Pantelis; Nobutaka Hattori; Shigeki Aoki
Journal:  Hum Brain Mapp       Date:  2017-05-04       Impact factor: 5.038

Review 5.  Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.

Authors:  David Lindenbach; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2013-10-07       Impact factor: 8.989

6.  Dosage effects of BDNF Val66Met polymorphism on cortical surface area and functional connectivity.

Authors:  Chao Wang; Yuanchao Zhang; Bing Liu; Haixia Long; Chunshui Yu; Tianzi Jiang
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

7.  Progression of brain atrophy in the early stages of Parkinson's disease: a longitudinal tensor-based morphometry study in de novo patients without cognitive impairment.

Authors:  Carlo Tessa; Claudio Lucetti; Marco Giannelli; Stefano Diciotti; Michele Poletti; Sabrina Danti; Filippo Baldacci; Claudio Vignali; Ubaldo Bonuccelli; Mario Mascalchi; Nicola Toschi
Journal:  Hum Brain Mapp       Date:  2014-01-22       Impact factor: 5.038

8.  Cortical Implications of Advancing Age and Disease Duration in Parkinson's Disease Patients with Postural Instability and Gait Dysfunction.

Authors:  Joshua N Herb; Swati Rane; David A Isaacs; Nelleke Van Wouwe; Olivia C Roman; Bennett A Landman; Benoit M Dawant; Peter Hedera; David H Zald; Joseph S Neimat; Scott A Wylie; Manus J Donahue; Daniel O Claassen
Journal:  J Parkinsons Dis       Date:  2016-05-05       Impact factor: 5.568

9.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

10.  Individual differences in frontal cortical thickness correlate with the d-amphetamine-induced striatal dopamine response in humans.

Authors:  Kevin F Casey; Mariya V Cherkasova; Kevin Larcher; Alan C Evans; Glen B Baker; Alain Dagher; Chawki Benkelfat; Marco Leyton
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.